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Genetically modified mice are indispensable for establishing the roles of platelets in
arterial thrombosis and hemostasis. Microfluidics assays using anticoagulated whole
blood are commonly used as integrative proxy tests for platelet function in mice. In the
present study, we quantified the changes in collagen-dependent thrombus formation
for 38 different strains of (genetically) modified mice, all measured with the same
microfluidics chamber. The mice included were deficient in platelet receptors, protein
kinases or phosphatases, small GTPases or other signaling or scaffold proteins. By
standardized re-analysis of high-resolution microscopic images, detailed information was
obtained on altered platelet adhesion, aggregation and/or activation. For a subset of
11 mouse strains, these platelet functions were further evaluated in rhodocytin- and
laminin-dependent thrombus formation, thus allowing a comparison of glycoprotein
VI (GPVI), C-type lectin-like receptor 2 (CLEC2) and integrin α6β1 pathways. High
homogeneity was found between wild-type mice datasets concerning adhesion and
aggregation parameters. Quantitative comparison for the 38 modified mouse strains
resulted in a matrix visualizing the impact of the respective (genetic) deficiency on
thrombus formation with detailed insight into the type and extent of altered thrombus
signatures. Network analysis revealed strong clusters of genes involved in GPVI signaling
and Ca2+ homeostasis. Themajority of mice demonstrating an antithrombotic phenotype
in vivo displayed with a larger or smaller reduction in multi-parameter analysis of
collagen-dependent thrombus formation in vitro. Remarkably, in only approximately
half of the mouse strains that displayed reduced arterial thrombosis in vivo, this was
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accompanied by impaired hemostasis. This was also reflected by comparing in vitro
thrombus formation (by microfluidics) with alterations in in vivo bleeding time. In
conclusion, the presently developed multi-parameter analysis of thrombus formation
using microfluidics can be used to: (i) determine the severity of platelet abnormalities;
(ii) distinguish between altered platelet adhesion, aggregation and activation; and (iii)
elucidate both collagen and non-collagen dependent alterations of thrombus formation.
This approach may thereby aid in the better understanding and better assessment of
genetic variation that affect in vivo arterial thrombosis and hemostasis.
Keywords: arterial thrombus formation, bleeding, collagen, glycoprotein VI, platelets, microfluidics
INTRODUCTION
Current concepts of platelet activation pathways in thrombosis
and hemostasis rely to a large extent on the summation of single
observations. Frequently, the role of a particular protein or
signaling pathway is deduced from the consequences of a genetic
knockout in mouse on platelet responses, such as in comparison
to changes in experimental arterial thrombosis and tail bleeding.
A large set of such studies has resulted in the concept of
collagen-induced arterial thrombus formation (1–4). Herein,
it is stipulated that the exposure of subendothelial collagen to
flowing blood is a key trigger to start shear-dependent thrombus
formation. Collagen causes platelet adhesion and furthermore
binds von Willebrand factor (VWF), which can decelerate
flowing platelets at high shear rate. Firm VWF/collagen-
mediated adhesion and subsequent platelet activation
requires synergy between the VWF receptor, glycoprotein
(GP)Ib-V-IX, and the collagen receptors, GPVI and integrin
α2β1 (5–8).
Collagen is known to induce a number of stimulating
pathways via GPVI, in particular: (i) activation of Src-family
and Syk tyrosine kinases, resulting in phospholipase C (PLC)γ2
activation and intracellular Ca2+ mobilization (2, 9); (ii)
additional Ca2+ influx via ORAI1 channels which couple to
the calcium sensor STIM1 in the reticular membrane (10); (iii)
activation of several isoforms of protein kinase C (PKC) (11),
phosphoinositide 3-kinases (PI3K) (12), and small GTPases, the
latter including CDC42, RAC1 and RHOA (13). Additional,
modifying signaling pathways include: (iv) activation of
phospholipase D, augmenting flow-dependent platelet activation
(14); and (v) activation of multiple (tyrosine) phosphatases, a
part of which act downstream of immunoreceptor tyrosine-based
inhibitionmotif (ITIM)-containing receptors. Such phosphatases
can have a direct or indirect platelet-stimulating (e.g., CD148,
DUSP) or a platelet-inhibiting effect (PECAM1, G6b-B) in
response to collagen (15). Together, these signaling routes co-
operate to control the activation state of the platelet fibrinogen
receptor, integrin αIIbβ3, the secretion of granular contents, and
the release of thromboxane-A2. Locally secreted or generated
soluble agonists, acting via G-protein coupled receptors (GPCR)
ensure the capture and incorporation of passing platelets into
an aggregate or thrombus (2–4). In a subset of platelets in the
thrombus, procoagulant activity is generated by Ca2+-dependent
activation of the anoctamin-6 (TMEM16F) channel (16),
regulating phosphatidylserine (PS) exposure and platelet
ballooning (17–19).
Although all these signaling components are known to play
a certain role in collagen-dependent thrombus formation, there
is still limited insight into the relative contribution of individual
proteins. In addition, it is unclear to which extent C-type
lectin-like receptor-2 (CLEC2), another receptor that signals
via tyrosine kinases (20, 21), is capable to regulate the process
of thrombus formation. The same holds for integrin α6β1, an
adhesive receptor, which mediates flow-dependent adhesion of
platelets to the matrix protein laminin (22).
In a recent synthesis approach, a quantitative evaluation was
made of the contribution of 431 mouse genes to experimental
arterial thrombosis and hemostasis in vivo, thereby revealing
several genes with a role in thrombosis without affecting bleeding
(23). For the total cohort of studies and mouse genes, it appeared
that microfluidics assays where thrombus formation is measured
in vitro—by whole blood perfusion over a collagen surface—
predict the consequences of a gene knockout on thrombosis
models in vivo (23). However, the standardmicrofluidic tests only
report on changes in platelet adhesion (surface area coverage,
SAC%), which is a limitation given that the recorded microscopic
images also contain information on platelet aggregate formation
(24, 25). In comparison, for human blood samples from a large
cohort of healthy subjects, it could be shown that a multi-
parameter image analysis can provide detailed information on
the sub-processes of platelet adhesion, aggregation and activation
at the same time (26).
To better understand the alterations in thrombus phenotypes
using microfluidics, we applied a similar multi-parameter
approach to quantitatively compare the effects of deficiency
of 37 signaling proteins on collagen-induced pathways. We
therefore re-analyzed earlier recorded microscopic images, in all




Mice were included from 38 strains, in each case with a
monogenetic or antibody-induced deficiency, as well as 22 sets
of corresponding wild-type or control mice, as described in the
original publications (see Table 1). As a selection criterion for
Frontiers in Cardiovascular Medicine | www.frontiersin.org 2 July 2019 | Volume 6 | Article 99
Nagy et al. Microfluidics Thrombus Formation in Mice
inclusion, microscopic images needed to be available from n ≥
3 animals per modified group and n ≥ 4 for wild-types. Scaled
effects on in vivo arterial thrombosis and tail bleeding are for the
majority of strains described previously (23).
In all cases, mouse blood was collected into anticoagulant
medium, consisting of PPACK (40µM), unfractionated heparin
(5 U/ml) and low molecular weight heparin (fragmin, 50
U/ml). Samples were immediately processed. For original data,
experiments were approved by the district government of
Lower Franconia (Bezirksregierung Unterfranken) and by the
Animal Experimental Committee in Hinxton/Cambridge. For
previously published data, experiments were approved by the
local Animal Experimental Committees as indicated in the
original publications (see references in Table 1).
Whole Blood Thrombus Formation Under
Flow
For all data sets, thrombus formation in whole blood under flow
was assessed with the Maastricht flow chamber (depth 50µm,
width 3mm, length 30mm) (24). In short, PPACK/heparin
anticoagulated blood (400–500 µl) was perfused for 3.5–
4.0min at room temperature at a wall shear rate of 1000
s−1 (where indicated 1700 s−1) over (i) Horm-type collagen
(100µg/ml, Nycomed Pharma, Munich, Germany), allowing
platelet interaction via GPIb, GPVI and integrin α2β1.
Where specified, two additional surfaces were used, similarly
as described before (24): (ii) VWF-binding peptide (VWF-BP,
12.5µg/ml, obtained from Prof. Dr. R. Farndale, Cambridge
University, UK) + laminin (50µg/ml, from human plasma,
Sigma-Aldrich, St. Louis MO, USA; binding integrin α6β1)
(22), and (iii) VWF-BP + laminin + rhodocytin (250µg/ml,
activating CLEC2) (54). Rhodocytin purified from Calloselasma
rhodostoma (55), was a kind gift of Prof. Dr. K. Clemetson (Bern
University, Switzerland).
After blood perfusion, platelet thrombi were rinsed with
modified Tyrode’s Hepes buffer (pH 7.45, 5mM Hepes, 136mM
NaCl, 2.7mM KCl, 0.42mM NaH2PO4, 1 mg/ml glucose, 1
mg/ml bovine serum albumin, 2mM CaCl2, 2mM MgCl2 and
1 U/ml heparin), and then stained during 1.5min flow with
one to three fluorescently labeled platelet activation markers.
These were: Alexa Fluor (AF)647 (or FITC) conjugated annexin
A5 (AF647: 1:200, Invitrogen Life Technologies, Carlsbad, CA,
USA/FITC: 1:1000, PharmaTarget, Maastricht, The Netherlands);
FITC anti-mouse CD62P mAb (1:40, rat-anti-mouse, Emfret
Analytics, Würzburg, Germany); and phycoerythrin (PE)-
labeled JON/A mAb (1:20, Emfret Analytics); all diluted in
modified Tyrode’s Hepes buffer. Residual labels were removed
by another perfusion for 2min with label-free Tyrode’s Hepes
buffer. Multiple brightfield and (if applicable) fluorescence
microscopic images were captured per surface, of which
three representative images were re-analyzed in a systematic
way (26).
For image recording, different fluorescence microscopic
systems were used (see references in Table 1), but always
containing a 60/63x oil objective and a sensitive CCD camera for
capturing enhanced-contrast, brightfield images.
Microscopic Image Analysis
For all mouse strains, the recorded 16-bit or 8-bit brightfield
and fluorescence images were re-analyzed using the same newly
developed scripts (one per image type), written in Fiji (56).
Scripts always opened a series of images one-by-one with a loop.
In each loop run, background illumination was corrected using a
fast Fourier transform bandpass filter, followed by manual setting
of a threshold and measurement of the surface area coverage.
For brightfield images, a series of Gray morphology conversions
was applied to reduce striping and to improve the detection
quality. Image conversion steps were as follows: a diamond large
sized close, followed by a medium sized circle close and a small
circle shaped dilate. Note that the first step increased the pixels
that were stronger in regions with many neighboring pixels, the
second step then rounded the shapes and additionally reduced
straight lines, while the final step (allowing alteration by user-
interface) served to obtain the best match with the original image.
The Fourier transform filter served to flatten the background
areas sufficiently for good analysis, with a minimal impact on the
structures. For brightfield images, large structures were filtered
down to 60 pixels, for the fluorescence images of annexin A5,
integrin and P-selectin images large structures were filtered down
to 65 pixels. Small structures were not filtered down, as these
contained structures of interest within the adhered platelets
(Supplementary Figure 1).
Using these scripts and by visually scoring the unprocessed
brightfield images, the following parameters of thrombus
formation were obtained (Table 2): surface area coverage of
adhered platelets (P1, %SAC); platelet aggregate coverage (P2,
%SAC); thrombus morphology score (P3, scale 0-5); thrombus
multilayer score (P4, scale 0-3); and thrombus contraction score
(P5, scale 0-3). Scoring was performed in comparison to a set
of pre-defined standard images (Supplementary Figure 1). For
the assessment of platelet activation, fluorescence images were
analyzed for PS exposure (P6, %SAC), P-selectin expression (P7,
%SAC) and integrin αIIbβ3 activation (P8, %SAC) (24).
Regardless of the image type, parameter values from three
images per experiment were averaged, thus resulting in a single
value per parameter and experiment. The image analysis and
scoring parameters were verified by different observers, who
were blinded to the experimental condition. Parameters of
experiments from the samemouse strain were combined as proxy
measures of platelet adhesion (P1), thrombus signature (P2-5),
and platelet activation (P6-8), as described before for human
platelets (26).
Network Analysis
A network of protein-protein interactions was built based on 37
investigated genes, using the STRING database (57), taking into
consideration the following settings: 1st shell interactors: <20
interactors, 2nd shell interactors: <60 interactors, confidence
level: medium to high. Networks were visualized in Cytoscape
version 3.7.0 (58).
Network clustering analysis was performed with the
Cytoscape app, MCODE to identify highly interacting nodes
using the following settings: degree cutoff: 2, node score cutoff:
0.2, K-core: 2 and maximum depth: 100 (59, 60).

































TABLE 1 | Overview of re-analyzed data sets on thrombus formation using the Maastricht flow chamber.







Ano1 Anoctamin-1 PF4-Cre Ano1 C57Bl/6 07 o n.d. n.d. - (18)
Ano6 Anoctamin-6 Ano6Gt(AW0382) C57Bl/6 07 o n.d. ↑ Prolonged bleeding (18)
Anxa1 Annexin A1 PF4-Cre Anxa1 C57Bl/6 22 o n.d. n.d. - (23)***
Apoe Apolipoprotein E Apoetm1Unc C57Bl/6 22 ↑ n.d. n.d. - (23)***
Bnip2 BCL2-interacting
protein 2
Bnip2tm1a C57Bl/6N 21 o n.d. n.d. - (23)***
Capn1 Calpain-1 Capn1tm1Ahc C57Bl/6 10 ↑ ↓ n.d. Delayed vessel occlusion (27, 28)





PF4-Cre Cdc42 C57Bl/6 x 129SV 20 o ↑ ↑ Accelerated vessel occlusion,
prolonged bleeding
(31)














Dusp3tm1Srah C57Bl/6 11 ↓ ↓ o Decreased pulmonary embolism,
small thrombus volume
(33)





Fpr2Tg(ACTB)#Jimw C57Bl/6 22 ↑ n.d. n.d. - (23)***




Gp6 GPVI Gp6tm1Beni C57Bl/6 03 ↓ ↓ o Reduced thrombus stability,
enhanced embolization
(37, 38)






Grm8tm1a C57Bl/6N 21 o n.d. n.d. - (23)***
Ifnar1 Interferon
receptor 1
Ifnar1tm1a C57Bl/6N 21 ↓ n.d. n.d. - (23)***
Itga2 Integrin α2 LoxP-Cre Itga2 C57Bl/6 x 129SV 05 ↓ ↓ o Reduced thrombus formation,
increased embolization
(5, 39)




















































































TABLE 1 | Continued









Kcnn4tm1Rklr C57Bl/6 x 129SV 16 o n.d. n.d. - (18)
Mpig6b Receptor G6B-b Mpig6btm1.1Arte C57Bl/6 24 ↓ n.d. ↑ Prolonged bleeding (41)
Orai1 Calcium channel
ORAI1
BMC Orai1−/− C57Bl/6 01 ↓ ↓ o/↑ Reduced thrombus formation and
stability
(42, 43)





Plcg2Ali5 C3HeB/FeJ 12 ↑ ↑ n.d. Increased pulmonary
thromboembolism
(46)
Pld1 Phospholipase D1 Pld1tm3Mafr C57Bl/6 02 o ↓ o Reduced thromboembolism, reduced
thrombus stability
(14)
Prkca Protein kinase C-α PrkcaMyh6/tetO/1Jmk C57Bl/6 06 ↓ ↓ o Delayed thrombus formation, no fecal
occult blood
(47, 48)
Prkcd Protein kinase C-δ Prkcdtm1Kin C57Bl/6 06 ↑ o n.d. Unchanged thrombus formation (47, 49)
Prkcq Protein kinase C-θ Prkcqtm1Litt C57Bl/6 06 ↑ n.d. n.d. Limited occlusion, thrombus instability (47)
Prkd2 Protein kinase D2 Prkd2tm1.1Daca C57Bl/6 17 ↓ n.d. o Unchanged bleeding (50)
Ptprj Phosphatase
CD148





Mx-Cre Rac1 C57Bl/6 08 ↓ ↓ ↑ Reduced thrombus formation and





PF4-Cre Rhoa C57Bl/6 x 129SV 08 o ↓ ↑ Unstable thrombus formation,
increased embolization
(13)**
Stim1 Regulator STIM1 BMC Stim1−/− C57Bl/6 01 ↓ ↓ ↑ Reduced thrombus stability, no vessel
occlusion
(42, 52)










Vps13atm1a C57Bl/6N 21 ↓ n.d. n.d. - (23)***
Shown are published changes in platelet deposition (SAC%) on collagen for mice with indicated genetic deficiencies in comparison to wild-type mice. Where indicated, GPVI and/or CLEC2 were rendered non-functional by injection of
antibodies. Further indicated are published effects of the gene deficiency (same mouse strain) on in vivo arterial thrombosis, pulmonary thromboembolism and/or (tail) bleeding.
BMC, bone-marrow chimera; DB, database; GOF, gain-of-function mutation; n.d., not determined. *Antibody-mediated deficiency of CLEC2 and/or GPVI; **microfluidics data not included in reference; ***only data for M1 published;
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TABLE 2 | Overview of microspotted surfaces (M) and parameters of image
analysis (P) for the assessment of thrombus formation.
M Microspot surface Platelet receptors
involved
M1 Collagen type I (VWF)* GPIb, GPVI, α2β1
M2 Rhodocytin + laminin + VWF-BP GPIb, CLEC2, α6β1
M3 Laminin + VWF-BP GPIb, α6β1
P Parameter of analysis Image Range Scaling
Platelet adhesion
P1 Platelet surface area coverage (%SAC) BF** 0 – 93.67 0 – 10
Thrombus signature
P2 Platelet aggregate coverage (%SAC) BF 0 – 49.17 0 – 10
P3 Thrombus morphology score BF 0 – 5.0 0 – 10
P4 Thrombus multilayer score BF 0 – 3.0 0 – 10
P5 Thrombus contraction score BF 0 – 3.0 0 – 10
Platelet activation
P6 PS exposure (%SAC) FL 0 – 12.23 0 – 10
P7 P-selectin expression (%SAC) FL 0 – 29.70 0 – 10
P8 Integrin αIIbβ3 activation (%SAC) FL 0 – 28.25 0 – 10
*Binds VWF from plasma. **BF, brightfield; FL, fluorescence.
Data Processing and Statistical Analysis
For each genetically modified strain and corresponding wild-
types, image data were averaged to obtain one parameter per
surface, of which mean and SD values were calculated. For
heatmap representation, mean values were univariate scaled
from 0 to 10 per parameter (24). Gene effect heatmaps were
constructed by subtracting scaled average values of the wild-type
(control) strain from those of the modified strain. For statistical
evaluation, a filter was applied, considering changes outside the
range of composite mean ± SD as a relevant difference between
modification and wild-type (26). Heatmap data were visualized
by (unsupervised hierarchical) cluster analysis using the program
R (61). For comparison of raw parameter values, a Kendall’s
tau-b correlation analysis was performed using SPSS (IBM SPSS
version 24, Armonk, NY, USA).
RESULTS
Microfluidics Analysis of Thrombus
Formation on Collagen of Multiple
Wild-Type Mouse Datasets
Microscopic brightfield and (annexin A5) fluorescence images
were collected from earlier performed whole blood perfusion
experiments with blood from 38 different strains of modified
mice and 22 corresponding wild-types (Table 1). Included
were experiments with strains (in majority published), that
were judged to be of sufficiently high quality and power
to allow re-analysis by newly developed image analysis
scripts (Supplementary Figure 1). From each experiment, five
parameters of thrombus formation were obtained (Table 2).
Platelet adhesion was quantified by the conventional analysis
of platelet SAC% (P1). Thrombus signature (26) was composed
of four parameters related to the thrombus buildup (ΣP2-
5), i.e., platelet aggregate SAC% (P2), thrombus morphology
score (P3), thrombus multilayer score (P4), and thrombus
contraction score (P5). As far as available, platelet activation
was assessed from fluorescence images of PS exposure (P6) (see
Supplementary Figure 1).
To establish the overall consistency of the combined databases
of the whole blood experiments, we compared the mean values
plus variation for each of the image analysis parameters P1-5
for the 22 wild-type control datasets. The calculated coefficients
of variation of means across the wild-type datasets ranged
from <12% (P3-5) to 23-25% (P1,2) (Supplementary Table 1).
For heatmap presentation, mean values for all wild-types (and
corresponding transgenic animals) were univariate scaled from
0-10 (Figure 1A). The obtained heatmap illustrated an overall
high cohesion of the data, yet also suggesting that wild-type
strains with mixed C57Bl/6 x 129SV background (databases 04,
05, 08, 16, 20) had a tendency for smaller P3-5 values. Overall,
these findings point to a high degree of comparability between
the various wild-type datasets.
To determine how the different parameters of collagen-
mediated thrombus formation correlated within our dataset of
wild-type and genetically modified mice, a correlation matrix
was constructed based on the Kendall’s tau-b correlation analysis
(Figure 1). All parameters showed a significant moderate to
strong correlation to each other (Kendall’s tau-b: 0.424–0.829).
Platelet adhesion (P1) correlated strongly to platelet aggregation
(P2), while it correlated moderately to thrombus morphology
(P3), multilayer (P4) and contraction (P5) (Kendall’s tau-b: 0.424-
0.572). Strongest associations were observed between platelet
aggregation (P2) and the thrombus scores (P3-5) (Kendall’s tau-b
0.55–0.65, p < 0.001). Furthermore, even stronger correlations
were seen between P3-5, i.e., the thrombus morphology,
multilayer and contraction scores (Kendall’s tau-b 0.76–0.83,
p < 10−10).
Comparing Thrombus Formation on
Collagen in Multiple Genetically Modified
Mice
As detailed in Table 1, the included 38 modified mouse strains
concern animals with defects of single genes, encoding for
proteins implicated in GPVI- and/or GPCR-related platelet
activation pathways, i.e., Csk, Fcer1g (FcR γ-chain), Gnaq (Gαq),
Orai1, Pik3cg (PI3Kγ), Pld1 (PLD1), Prkca (PKCα), Prkcd
(PKCδ), Prkcq (PKCθ), Prkd2 (PKD2), Stim1, Stim2 or Syk.
In addition, the list contains mice with genetic deficiencies
of the small GTPases, Cdc42, Rhoa or Rac1; deficiencies of
protein (tyrosine) phosphatases Dusp3, Mpig6b (G6b-B), or
Ptprj (CD148); deficiencies of other adhesive receptors, such as
Itga2 (integrin α2), Itgb1 (integrin β1) or Cd36 (GPIV); defects
linked to altered PS exposure, i.e., Ano1 (TMEM16A), Ano6
(TMEM16F), Capn1 (calpain-1) or Kcnn4. Other mice with
single gene deficiencies came from an earlier undertaking to
find novel proteins implicated in thrombosis and hemostasis
(23), namely Anxa1 (annexin 1), Apoe (plasma lipoprotein
component), Bnip2 (CBL2-interacting protein), Dlg4 (scaffold
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FIGURE 1 | Consistency of collagen-dependent thrombus formation between multiple wild-type mouse datasets. Blood from wild-type (WT) mice (databases as
indicated in brackets) was perfused over collagen at a shear rate of 1000 s−1 (in two cases 1700 s−1), and parameters of thrombus formation were obtained by
re-analysis of random brightfield images. Investigated wild-type mice (n = 22) had a C57Bl6 genetic background or, where indicated, a mixed C57Bl6 x 129SV
background (M) or other background (O). For full details, see Table 1. (A) Heatmap of mean parameters, univariate scaled (0–10) across all mouse strains. Parameter
clustering was as follows: platelet adhesion: P1 (platelet SAC%); thrombus signature: P2 (platelet aggregate SAC%), P3 (thrombus morphology score), P4 (thrombus
multilayer score), P5 (thrombus contraction score); and platelet activation: P6 (PS exposure). Also indicated (black bars on the right) are the overall scaled values of
platelet adhesion (P1) and thrombus signature (ΣP2-5). The wild-type datasets were arranged based on the alphabetical order of the (genetically) modified mice.
(B,C) Correlations between parameters of thrombus formation for all cohorts of mice strains. Shown are Kendall’s tau-b correlation coefficients (B) and corresponding
p-values (C).
protein), Fpr2 (formyl peptide receptor), Grm8 (glutamate
receptor), Ifnar1 (interferon receptor) or Vps13a (vacuolar
sorting protein). In addition, a mutated mouse strain with a
Plcg2 gain-of-function (GOF, constitutive active PLCγ2) was
incorporated (46). Given the ability of antibodies JAQ1 and
INU1 to specifically cause platelet depletion from GPVI or
CLEC2, respectively, after in vivo injection into mice (5) we
also included strains with such antibody-induced GPVI and/or
CLEC2 deficiencies.
For assessment of the effects of (genetic) deficiency, scaled
values per parameter were calculated for each of the 38 modified
mouse strains and compared to those of the corresponding
wild-types (Supplementary Figure 2). A subtraction heatmap
was generated to pinpoint the effects of genetic modification,
in which differences outside the range of (composite) means
± SD were considered as being relevant. The heatmap data
could be ranked based on alterations in thrombus signature
(Figure 2A) or on differences in platelet adhesion (Figure 2B).
With either way of ranking, profound quantitative differences
were observed in the majority of the thrombus formation
parameters, when comparing the 38 modified mouse strains.
Thrombus signatures were suppressed, in a decreasing order
(Figure 2A), by deficiencies in Syk, GPVI/CLEC2, GPVI,
Fcer1g, Gnaq, Rac1, Prkd2, Prkca, Stim1, Itga2, Orai1, CLEC2,
Mpig6b, Pik3cg, Csk, and Ptprj. In contrast, this thrombus
marker was elevated, in an increasing order, by deficiencies in
Prkcq, Capn1, Plcg2 (gain-of-function mutation), Apoe, Prkcd,
and Fpr2.
The ranking based on altered platelet adhesion revealed
several similarities, but also marked differences. Defects in Syk,
GPVI, Rac1, Stim1, and Itga2 resulted in a strong suppression
of both platelet adhesion and thrombus signature. Relative
larger effects on thrombus signature—in comparison to platelet
adhesion—were apparent for mice with defects in Fcer1g, Prkd2,
and Prkca (reduced thrombus formation), as well as for mice with
defective members of the PKC family, Prkcd and Prkcq (increased
thrombus formation). Relative increases in platelet adhesion
were only seen for mice with deficiencies in Kcnn4, Ano1, and
Capn1. In general, these heatmaps demonstrated that the ranking
based on changes in thrombus signature (Figure 2A) can provide
additional insight into the ’thrombogenic” consequences of a
gene defect, in comparison to a ranking based on altered platelet
adhesion (Figure 2B).
Microfluidics Analysis of Thrombus
Formation on Collagen and Other Surfaces
For a subset of 11 genetically modified mice strains, the same
microfluidic device was used to assess whole blood thrombus
formation on collagen-I (M1) plus two additional microspots, i.e.,
rhodocytin/laminin (M2) and laminin (M3), both co-coated with
VWF-BP to induce shear-dependent platelet adhesion (Table 2).
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FIGURE 2 | Multi-parameter comparison of collagen-dependent thrombus formation for 38 (genetically) deficient mice. Whole blood from mice with indicated genetic
or antibody-induced defects as well as from corresponding wild-type mice was perfused over collagen-I. Parameters of thrombus formation were as indicated in
Figure 1. For detailed information on mouse strains, see Table 1. Mean parameters per strain were scaled (0–10) across all wild-types (n = 22) and (genetically)
modified mice (n = 38), as for Figure 1. Subtraction heatmaps showing differences between indicated genetic (or antibody-mediated) deficiency in comparison to
wild-type, after filtering for differences outside the range of (composite) mean ± SD, to select relevant changes. (A) Ranking of genes based on effect on thrombus
signature (ΣP2-5), as shown in black bars on the right. Colors indicate unchanged (black), decreased (green) or increased (red) parameters. (B) Ranking of genes
based on effect on platelet adhesion (P1), as indicated in black bars. Colors represent unchanged (black), decreased (green) or increased (red) parameters.
Non-subtracted heatmap values are provided in Supplementary Figure 2.
As clarified before, immobilized rhodocytin triggers CLEC2-
induced platelet activation (26, 54), whereas laminin surfaces
allow platelet adhesion via integrin α6β1 (22). For the same
subset of mice, the formed thrombi were post-stained in three
colors to quantify PS exposure (P6), P-selectin expression (P7)
and integrin αIIbβ3 activation (P8), using procedures previously
established for human platelet thrombi (26). Representative
images from each of the microspots using wild-type blood
are depicted in Figure 3. In comparison to collagen-I (M1),
rhodocytin/laminin (M2) was less thrombogenic, with only
moderately activated platelets that formed small aggregates. The
laminin microspot (M3) only triggered adhesion of a monolayer
of spreading platelets.
For these 11 genetically modified mouse strains
plus corresponding wild-type mice, we again listed the
scaled parameters (P1-8) for each microspot (M1-3)
(Supplementary Figure 3). The ensuing subtraction heatmap
revealed major reductions in platelet adhesion and thrombus
signature at surface M1 for the animals with deficiencies in
Csk, Ptprj, Mpig6b (tyrosine protein kinase, phosphatases and
ITIM receptor, respectively); and, to a clearly lesser extent, for
deficiencies in Ifnar1, Vps13a and Anxa1 (Figure 4). For the
kinase and phosphatase knockouts, this extended to a reduction
in platelet activation parameters (P6-8) at M1, and furthermore
to lower P1-2 values at the other microspotsM2-3.
Markedly, for several of these mice, also gain-of-platelet-
functions could be detected. In this case, increased parameters
P4-6 were distributed over M1 (deficiencies in Apoe and Fpr2)
and M2 (deficiency in Grm8). Another remarkable finding
was that, for the majority of mice, parameters at the laminin
surface (M3) were unchanged. This suggested that laminin-
platelet interactions are relatively insensitive to these genetic
modifications. Next to the ranking based on changes in platelet
adhesion (Figure 4B), the ranking of genes according to changes
in overall thrombus signature (Figure 4A) appeared to be
a valuable addition in the description of the alterations in
platelet properties.
Linking Microfluidics Outcomes to
Thrombosis and Hemostasis in vivo
Recently, we described a systematic procedure to compare the
consequences of genetic knockout in mice for experimentally
induced (collagen-dependent) arterial thrombosis and
hemostasis (23). For the 38 deficiencies, it was thus of interest
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FIGURE 3 | Microscopic imaging of whole blood thrombus formation on adjacent microspots. Whole blood from wild-type mice (DB 24) was flowed for 3.5min at
1000 s−1 over three consecutive microspots of collagen-I (M1, upper row), rhodocytin/laminin/VWF-BP (M2, middle row), and laminin/VWF-BP (M3, lower row).
Shown are representative brightfield and fluorescence microscopic images of the thrombi formed. Triple staining was performed with AF647-annexin A5,
FITC-anti-CD62P Ab, and PE-JON/A Ab. Also indicated are the types of parameters (P1-8) taken from the image sets. Bar, 50µm.
to compare the results of the current extended microfluidic
assay (M1, P1-5) with the previously reported changes in arterial
thrombosis tendency and tail bleeding in vivo. Hence, per
modified mouse strain, the recorded changes (Table 1) were
listed as being a reduced/unchanged/increased thrombosis
phenotype and as a prolonged/unchanged/shortened bleeding
time. Figure 5 gives the comparison of these in vivo effects
with altered parameters of in vitro thrombus formation
using microfluidics.
Strikingly, the majority of mice demonstrating an
antithrombotic phenotype in vivo manifested with a larger
or smaller reduction in collagen-dependent thrombus formation
in vitro (Figure 5). We noted only a few exceptions: (i) mice
deficient in Cdc42 with an apparently prothrombotic phenotype,
but for unknown reasons no effect in vitro; (ii) mice deficient
in Pld1 (where in vitro thrombus formation was only impaired
at a higher shear rate of 1700 s−1) (14); and (iii) Cd36-deficient
mice (requiring a thrombospondin surface for altered in vitro
thrombus formation) (29). Also, the impaired arterial thrombosis
reported for Capn1−/− mice (27) did not match with a measured
higher platelet adhesion under flow, although it should be noted
that the latter mice showed a complex pattern of increased and
decreased platelet activation parameters in vitro (28).
Markedly, in the mouse strains with a reduced arterial
thrombosis tendency in vivo, only approximately half of these
were accompanied with a hemostatic defect (Figure 5). This
was also reflected by comparing in vitro thrombus formation
(by microfluidics) with alterations in bleeding time. Mice with
reduced in vitro thrombus formation, but unchanged or slightly
prolonged bleeding times, included animals with deficiencies
in the collagen receptors Gp6 and Itga2; the protein kinases
Prkd2 and Prkca; and the protein phosphatases Ptprj and
Dusp3. This may suggest that the collagen receptors (and hence
collagen itself) and the (de)phosphorylating proteins within the
downstream signaling pathways are not essential for hemostasis.
This may suggest that the collagen receptors (and hence collagen
itself) and the (de)phosphorylating proteins are not uniquely—
perhaps redundantly—required for platelet functions at lower
shear rates such as during hemostasis. The same mouse genes
were also previously characterized as having a distinct role in
arterial thrombosis and hemostasis (23).
Network Modeling to Predict Novel
Proteins Implicated in Mouse Platelet
Functions
Based on the 37 different mouse genes/proteins that were
analyzed for effects on collagen-dependent whole blood
thrombus formation, we constructed a network using the
biological STRING (Search Tool for the Retrieval of Interacting
Genes/Proteins) database, in order to be capable to depict
additional protein-protein interactions. Accordingly, a network
was established containing in total 117 nodes (37 core and 80
novel nodes) and 1142 edges (interaction score: medium to
highest confidence: 0.40–0.99). Reactome pathways that were
highly represented in the network were: platelet activation,
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FIGURE 4 | Multi-parameter comparison of thrombus formation on three microspots for 11 mouse strains with genetic deficiencies. Whole blood from mice with
indicated genetic defects or corresponding wild-types was perfused over three microspots (M1-3), as for Figure 3. Brightfield images (P1-5) and fluorescence images
(P6, AF647-annexin A5; P7, FITC anti-CD62P Ab; P8, PE-JON/A Ab) were analyzed for each microspot. Per microspot, parameter values were univariate scaled
(0-10) across all mouse strains. (A) Subtraction heatmap of differences between deficient and wild-type strains, filtered for changes outside the range of (composite)
mean ± SD, to select relevant changes. Genes were ranked based on effects on thrombus signature (ΣP2-5) across microspots M1-3, as shown in black bars.
Colors represent unchanged (black), decreased (green) or increased (red) parameters. (B) Subtraction heatmap with ranking based on gene effects on platelet
adhesion (P1), as indicated in right black bars.
signaling and aggregation (count in gene set: 37 of 242; false
discovery rate: 3.25e−39), hemostasis (count in gene set: 44 of
489; false discovery rate: 1.5e−38), signal transduction (count
in gene set: 68 of 2430; false discovery rate: 2.14e−32), GPVI-
mediated activation cascade (count in gene set: 18 of 34; false
discovery rate: 2.07e−26) and G alpha (12/13) signaling events
(count in gene set: 18 of 68; false discovery rate: 2.64e−22).
The 37 core nodes were color- and size-coded, based on the
established gene effects on thrombus signature M1PΣ(2-5), and
then indicated three typical clusters of genes/proteins with large
size effects (Figure 6): (i) Gp6 with associated receptors Fcer1g
and kinase Syk (cluster score: 7; #nodes: 19; #edges: 63); (ii)
the low-molecular weight GTPases Rac1 and Cdc42 together
with Itga2 and Itgb1 (cluster score: 5.24; #nodes: 22; #edges:
55); and (iii) Ca2+-regulating signaling components, Stim1,
Stim2 and Orai1 (cluster score: 4; #nodes: 4; #edges: 6). Out
of the 80 novel nodes, 12 genes have been previously shown
to modify in vivo arterial thrombosis and/or bleeding (Cblb,
Cttn, Gnai2, Gria1, Itga6, Lat, Lcp2, Ldlr, Pik3cb, Pik3r1, Rock2,
Vav1) (23). Color-coding of the same network nodes for gene
effects on platelet adhesion revealed as most notable changes the
above-mentioned gain-of-function effects of Ano1, Kcnn4 and
Capn1 (Supplementary Figure 4).
DISCUSSION
In this paper, we applied standardized analysis procedures
in order to allow detailed and quantitative comparison of
the changes in platelet functions in multiple genetically
modified mice, using microfluidic methods of collagen-
dependent thrombus formation under shear conditions. For
this purpose, we re-analyzed sets of microscopic brightfield
and fluorescence images, using defined semi-automated scripts,
resulting in quantitative parameters of platelet adhesion,
platelet aggregation (defined as thrombus signature) (26), and
platelet activation. The underlying rationale was that earlier
captured images provide more relevant information than
only a platelet surface area coverage, and thus can provide
additional insight into the complex process of thrombus
formation. For a subset of mice, it was also possible to
extend this complex phenotyping of thrombus formation to
other, non-collagen surfaces with additional parameters of
platelet activation.
Recent work has shown that multiple platelet function
assessment by whole blood microfluidic assays provides novel
insights, for instance into the changes in human platelets
linked to normal genetic variation (26, 62) and in mouse
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FIGURE 5 | Effects of genetic modification on arterial thrombosis and tail
bleeding in comparison to collagen-dependent thrombus formation using
microfluidics. Effects of genetic or antibody-induced defects of concerning
mouse strains on arterial thrombosis and tail bleeding was obtained from the
literature (see Table 1). Effects were classified as being unchanged (black),
antithrombotic/prolonged bleeding (green) or prothrombotic/shortened
bleeding (red), according to procedures described before (23). White color
indicates that information is lacking. Heat mapped data were ranked based on
summative effects on all thrombus formation parameters (ΣP1-5) from
surface M1.
platelets due to co-activation by interacting chemokines (63). The
present comparative quantitative analysis of changes in thrombus
formation in multiple genetically or antibody-induced modified
mice now also allows to evaluate the assay outcomes for changes
in specific platelet functions. Here, we could identify a partial
distinction between genes/protein affecting platelet adhesion and
those altering platelet aggregation properties (collectively termed
as thrombus signature). For instance, it seems that the murine
Csk, Mpig6b and Ptprj have a relatively large role in flow-
dependent platelet adhesion. Markedly, for Csk, Mpig6b, and
Ptprj this effect is extended to also a reduced adhesion at the
non-collagen surface M2. On the other hand, the processes of
platelet adhesion and aggregate formation are also related, as
shown by an overall consistent correlation between adhesion
and aggregation parameters (Kendall’s tau-b = 0.42-0.68). A
similar conclusion was drawn earlier from the analysis of
thrombus formation in blood samples from 94 healthy subjects,
also pointing to the existence of a subject-dependent thrombus
signature (26).
In comparison to the collagen surface (M1), for the 11
mouse strains analyzed, we observed in general smaller gene
effects at the two other surfaces (M2-3), which mediate
platelet adhesion via GPIb-V-IX and α6β1 with or without
CLEC2 (rhodocytin). Accordingly, it seems that, at least
in part, distinct sets of genes/proteins are implicated in
the platelet adhesion to non-collagen surfaces than to the
collagen surface. Clearly in vivo thrombus formation is not
purely mediated by collagen, but rather is the result of
platelet interactions with a mixture of different extracellular
matrix proteins.
The present data set also includes new findings with
unpublished blood samples from mice deficient in Rhoa
and Syk. The Rhoa defect did not appear to influence
platelet adhesion nor thrombus signature parameters at the
shear rate of 1000 s−1, which is in support of the earlier
conclusion that platelet RHO-A becomes relevant for thrombus
formation at high (pathological) shear rates (13). In contrast,
genetic deficiency in Syk resulted in a strong reduction of all
platelet and thrombus parameters on collagen. This highlights
the importance of SYK signaling in collagen-dependent
thrombus formation.
Given the earlier established correlation between the outcome
of microfluidic tests (in terms of platelet surface area coverage)
and experimental arterial thrombosis in mice (23), it was
of interest to evaluate for the current mouse strains how a
more detailed analysis (considering more thrombus parameters)
contributes to this relationship. Such a comparison clearly
has limitations, such as the wide variety of methods and test
outcomes of the in vivo thrombosis measurements, making a
clear differentiation between moderate and strong phenotypes
difficult (23); and furthermore, the absence of coagulation and
vessel wall components other than collagen in the in vitro
approach. Nevertheless, a ranking of the investigated mouse
strains according to overall changes in thrombus parameters
(including platelet adhesion and aggregation) showed a good
reflection with published changes in arterial thrombosis in
vivo. On the other hand, for a considerable set of genes,
a changed thrombus formation in vitro (and mostly in
vivo) was not associated with an altered bleeding time.
In several cases, a discrepancy is well explainable. For
instance, defects in platelet Clec1b (as a non-collagen receptor)
(64) or in Ano6 (an isolated defect of platelet-dependent
coagulation) (18), will not be picked up by flow assays
over collagen with anticoagulated blood. A striking example
is Gp6. Whereas, GPVI deficiency overall impairs thrombus
formation in vitro as well as arterial thrombosis in vivo,
mouse tail bleeding times are only moderately prolonged (37,
38). In line with that, mild bleeding symptoms have been
reported in patients with a defect in the GP6 gene (65, 66).
Hence, this gene does likely have a restricted role, which
is in line with the constructed network indicating multiple
GPVI-linked proteins that contribute to both thrombosis
and hemostasis.
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FIGURE 6 | Network of protein-protein interactions in collagen-dependent thrombus formation. Network, constructed from the STRING database and visualized in
Cytoscape, of murine protein-protein interactions with as seed the 37 investigated core genes. The network contained 117 nodes (37 core nodes, 80 novel nodes)
and 1142 edges. Core nodes of the network were color- and size-coded based on altered thrombus signature (ΣP2-5) at surface M1. Green color intensity (larger
size) of nodes points to a stronger reducing effect, and red color intensity (large size) to a stronger stimulating effect in comparison to wild-type. Novel nodes are
indicated in gray.
Translation of the current evaluation of genes in murine
thrombus formation to human pathophysiology can—taking
into account the above—provide better insight into the genetic
background of human platelet function abnormalities and how
these can relate to thrombotic and bleeding disorders. Indeed,
for homologs of several of the genes analyzed in this paper,
e.g., human ORAI1 and STIM1, mutations have been identified
that link to defective collagen-dependent thrombus formation in
vitro (67). By applying an extended image analysis, a detailed
description of the formed thrombi can be generated. This
can aid in the identification of the defective part (platelet
adhesion, aggregation or procoagulant response) of the process
of thrombus formation in patients with an unexplained increased
risk for either thrombosis or bleeding. Extended analysis of the
available mouse data and summation in the form of a network
can also contribute to a more targeted approach to select novel
candidate genes and proteins, possibly affecting platelet functions
in a positive or negative way.
Moreover, by applying new knowledge and techniques, in
the present paper, new insights were gained from previously
performed mouse experiments. In such a manner, our study
may contribute to the 3R approaches by reducing, refining and
replacing animal experiments.
Taken together, we conclude that the presently developed
multi-parameter analysis of thrombus formation on microspots
using microfluidics can be used to: (i) determine the
severity of platelet abnormalities; (ii) distinguish between
altered platelet adhesion, aggregation and activation;
and (iii) elucidate both collagen and non-collagen
dependent platelet changes. This approach may thereby
aid in the better understanding and better assessment
of the changes in platelets that affect arterial thrombosis
and hemostasis.
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